Top 10 Biotech Companies & Market Share 2008

1,948 views
1,698 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,948
On SlideShare
0
From Embeds
0
Number of Embeds
6
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Top 10 Biotech Companies & Market Share 2008

  1. 1. 2008<br />Biotech Market Share Analysis <br />
  2. 2. Biotechnology Market<br />Sales of biologics amounted to $75 billion in 2007--just over 10 percent of the estimated $712 billion spent on prescription drugs last year. <br />The combined market share of the top ten companies made up the bulk of those sales, coming to $61.4 billion.<br />Sales of biotech drug grew 12.5 percent in 2007--twice as fast as the pharmaceutical market. <br />
  3. 3. Biotechnology Market Share<br />
  4. 4. TOP 10 BIOTECH COMPANIES BY SALES--AND A LOOK AT WHAT'S NEXT IN THEIR PIPELINES<br />
  5. 5. 1. Amgen<br />2007 Sales: $15.9 billion<br />Market share: 21.3$<br />CAGR: 27%<br />
  6. 6. What Amgen has: <br />Amgen has five of the 22 biotech blockbusters currently on the market--tied only with Roche. <br />Marketed by Amgen and Wyeth, Enbrel tops this list as the world's bestselling biologic. <br />The drug is indicated for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosingspondylitis and moderate to severe plaque psoriasis. <br />1. Amgen<br />
  7. 7. 1. Amgen<br />What Amgen has: <br />Enbrel, which competes with Remicade and Humira, brought in $5.2 billion in sales in 2007.<br />Amgen saw sales of anemia drugs Arenesp and Epogen take a hit last year when the two garnered black box warnings for heart and vascular problems at high doses.<br /> Still, the second and eighth ranked blockbusters racked up $4.4 billion and $2.9 billion, respectively. <br />
  8. 8. 1. Amgen<br />What Amgen has: <br />Neulasta and Neupogen (which treat a lack of certain white blood cells caused by cancer and chemo) round out the company's blockbusters.<br />What to watch for: <br />Amgen's next big up-and-coming drug is the osteoporosis treatment Denosumab.<br /> The drug has already been submitted for FDA review and, if approved, could bring in $2 billion to $3 billion in sales a year.<br />
  9. 9. 2. Roche/Genentech<br />2007 Sales: $15.4 billion<br />Market share: 20.6%<br />CAGR: 33.5%<br />
  10. 10. What they have: <br />Roche's biggest biologic blockbuster is Rituxan, a rheumatoid arthritis and non-Hodgkins lymphoma remedy that raked in $2.2 billion in sales in 2007. <br />Other blockbusters include the breast cancer treatment Herceptin ($1.2 billion) and Avastin ($2.4 billion), which is indicated for colon or rectal cancer, non-small cell lung cancer and HER2 negative breast cancer. <br />Anemia drug Neorecormon and Lucentis for wet AMD round out Roche and Genentech's five biggest biologics.<br />2. Roche/Genentech<br />
  11. 11. What to look for: <br />Roche and Genentech have two new biologics in their late-stage pipeline. <br />These are ocrelizumab, a monoclonal antibody for rheumatoid arthritis, and pertuzumab, another MAb for metastatic breast cancer. <br />Additional indications for Avastin, Lucentis, Xolair are also in the works.<br />2. Roche/Genentech<br />
  12. 12. 3. Johnson & Johnson <br />2007 Sales: $6.2 billion<br />Market share: 8.4%<br />CAGR: 3%<br />
  13. 13. What they have: <br />J&J's bestselling biologic is Remicade ($3.3 billion). <br />Like the other anti-TNFs on this list, Remicade is approved for treating a host of immune diseases including plaque psoriasis, rheumatoid arthritis, psoriac arthritis, adult Crohn's disease, pediatricCrohn's disease, ulcerative colitis and ankylosingspondylitis. <br />The company's only other biotech blockbuster is Procrit, which rounded up $2.2 billion in 2007.<br />3. Johnson & Johnson <br />
  14. 14. What to look for: <br />Johnson & Johnson has filed two biologics for approval. <br />The psoriasis treatment ustekinumab is on the verge of winning FDA approval, having been backed by an FDA expert committee. <br />Golimumab--a human monoclonal antibody for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosingspondylitis--is also awaiting an FDA decision.<br />3. Johnson & Johnson <br />
  15. 15. 4. Novo Nordisk<br />2007 Sales: $5.8 billion<br />Market share: 7.8%<br />CAGR: 17.6%<br />
  16. 16. What they have:<br />Denmark-based Novo Nordisk's only blockbuster is NovoRapid, a fast-acting insulin product.<br />4. Novo Nordisk<br />
  17. 17. What to look for: <br />Novo Nordisk has three experimental treatments awaiting FDA approval. <br />NovoMix is a Type 1 and 2 diabetes treatment, and Activelle is a low-dose hormone replacement therapy. <br />Novo's most anticipated new therapy is the anti-diabetic drug Liraglutide. Liraglutide, which is a new class of antidiabetic medications called GLP-1 analogues, improved glucose control in late-stage clinical studies. <br />The drug is also in Phase II testing for obesity.<br />4. Novo Nordisk<br />
  18. 18. 5. Eli Lilly<br />2007 Sales: $3.9 billion<br />Market share: 5.2%<br />CAGR: 4.7%<br />
  19. 19. What they have: <br />Eli Lilly has only one biologic blockbuster, despite the fact that it ranks fifth in overall biologic sales. <br />Humalog, a Type 1 and 2 diabetes treatment, brought in $1.5 billion in sales in 2007. <br />The company's big sellers include Forteo, a synthetic form of the natural occurring hormone that treats osteoporosis in men and women, and Xigris, a treatment for sepsis. <br />About 25 percent of Lilly's 2007 sales came from biotech medicines.<br />5. Eli Lilly<br />
  20. 20. 5. Eli Lilly<br />What to look for: <br />Biotech molecules also represent approximately one-third of the Lilly's current pipeline, including potential treatments targeting Alzheimer's disease, cancer and diabetes, according to a recent release. <br />Lilly is working with MacroGenics to develop teplizumab, a humanized anti-CD3 monoclonal antibody for Type 1 diabetes which is in Phase III trials. <br />The company is also partnered with Canadian biotech BioMS to develop dirucotide, a multiple sclerosis treatment. <br />
  21. 21. 6. Sanofi-Aventis<br />2007 Sales: $3.2 billion<br />Market share: 4.3%<br />CAGR: 37.7%<br />
  22. 22. What they have: <br />Sanofi's top-selling biotech blockbuster is Lantus, a Type 1 and 2 diabetes treatment. <br />The company also markets a host of vaccines through Sanofi Pasteur, the vaccine division of Sanofi-Aventis.<br />6. Sanofi-Aventis<br />
  23. 23. What to look for: <br />Currently, only 10 percent of the drugs Sanofi makes are biologics; the company wants to boost that number to 20 or 30 percent by 2012. <br />Sanofi is collaborating with Regeneron on its drug Aflibercept (VEGF Trap), a cancer drug in late-stage trials for prostate and lung cancer.<br />6. Sanofi-Aventis<br />
  24. 24. 7. Abbott<br />2007 Sales: $3.1 billion<br />Market share: 4.2 $<br />CAGR: 119.1%<br />
  25. 25. What they have: <br />Abbott has two biotech blockbusters on the market. <br />Humira, a monoclonal antibody, competes with Remicade and Enbrel. <br />It's approved for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosingspondylitis, Crohn's disease, and plaque psoriasis. <br />Synagis treats respiratory syncytial virus, the leading cause of hospitalization in babies under a year.<br />7. Abbott<br />
  26. 26. 7. Abbott<br />What to look for: <br />Abbot is exploring new indications for Humira. <br />It's also advancing a new biologic for autoimmune diseases. <br />ABT-847 is in late-stage development for psoriasis and Crohne's disease. <br />In addition, Abbott teamed up with Genentech in 2007 to develop and commercialize ABT-263 and ABT-869. <br />
  27. 27. 8. Merck KGaA<br />2007 Sales: $2.7 billion<br />Market share: 3.6%<br />CAGR: 17.9%<br />
  28. 28. What they have: <br />When Merck KGaA bought out Serono in 2006 it inherited Rebif, a top-selling multiple sclerosis drug. <br />Merck is also one of three companies partnered on cancer drug Erbitux (along with ImClone and Bristo-Myers Squibb, which are not on this list).<br />The drug is approved for head and neck and colorectal cancer.<br />8. Merck KGaA<br />
  29. 29. What to look for: <br />Merck KGaA has filed two additional indications for Erbitux and has a new formulation of Rebif in the works.<br /> The company is also conducting late-stage testing for atacicept, an experimental rheumatoid arthritis treatment.<br />8. Merck KGaA<br />
  30. 30. 9. Schering-Plough <br />2007 Sales: $2.5 billion<br />Market share: 3.4%<br />CAGR: 1.4%<br />
  31. 31. What they have:<br />Schering-Plough, which markets J&J's Remicade outside of the U.S, racked up $1.6 billion in sales in 2007. <br />The company's pegylated interferon Hepatitis C injection Peg-Intron also brought in $911 million.<br />9. Schering-Plough <br />
  32. 32. What to look for: <br />Schering is partnered with J&J's Centocor on golimumabfor rheumatoid arthritis, ankylosingspondylitis, psoriatic arthritis and ulcerative colitis. <br />The company beefed up it's biotech pipeline with the $14 billion  acquisiton of OrganonBiosicences last year.<br />9. Schering-Plough <br />
  33. 33. 10. Wyeth<br />2007 Sales: $2.2 billion<br />Market share: 3%<br />CAGR: 38.4%<br />
  34. 34. What they have: <br />Wyeth's top-selling biologic is Enbrel, which it markets with Amgen. <br />The monoclonal antibody is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosingspondylitis, psoriatic arthritis and chronic moderate to severe plaque psoriasis.<br />10. Wyeth<br />
  35. 35. What to look for:<br />Bapineuzumab--currently in Phase III development--is a humanized monoclonal antibody being investigated for the treatment of Alzheimer's disease and possibly glaucoma.<br />10. Wyeth<br />
  36. 36. Thank You<br />

×